Jean-Claude Ansquer

LIPOPROTEIN SUBFRACTIONS ARE ASSOCIATED WITH ISCHEMIC STROKE AMONG 9,795 PATIENTS IN THE FIELD TRIAL

ANTHONY C. KEECH, Peter Paul Toth, Andrzej S. Januszewski, Rachel L O'Connell et autres

au (code pays fourni par la source)

Abstract WP219: Lipoprotein Subfractions Are Associated With Stroke Among 9,795 Patients in the Field Trial

Peter Paul Toth, ANTHONY C. KEECH, Andrzej S. Januszewski, Rachel L O'Connell et autres

Background: In the FIELD trial, a 5-year randomized double-blind placebo-controlled trial of fenofibrate vs. placebo in 9,795 adults with type 2 diabetes (T2D), the only standard lipid parameter correlating with microvascular (renal) events was triglycerides. Given the high prevalence of stroke among …

us, au, fi, sg, nz (code pays fourni par la source)

Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study

Boris Waldman, Jean-Claude Ansquer, DAVID R. SULLIVAN, Alicia Josephine Jenkins et autres

au, fr, sg, gb, fi, nz (code pays fourni par la source)

Systematic literature review and meta-analysis of dual therapy with fenofibrate or fenofibric acid and a statin versus a double or equivalent dose of statin monotherapy

Mario Ouwens, Jos Nauta, Jean-Claude Ansquer, Stefan Driessen

OBJECTIVE: To assess the efficacy of fenofibrate and statin dual therapy versus a double or equivalent dose of statin monotherapy. METHODS: A systematic literature search and meta-analysis was performed for publications before 1 January 2014 in MEDLINE, Embase, and BIOSIS Previews, among …

gb (code pays fourni par la source)

Effects of Fenofibric Acid on Diabetic Macular Edema: The MacuFen study

Pascale Massin, Tünde Pető, Jean-Claude Ansquer, Patrick Aubonnet et autres

PURPOSE: Fenofibrate reduced progression of diabetic retinopathy in two large randomized studies. The effect of 135 mg fenofibric acid on diabetic macular edema (DME) was evaluated in subjects with existing DME. METHODS: In this double-blind, randomized, placebo-controlled study, 110 subjects with DME …

fr, gb, mx, ch (code pays fourni par la source)

Pharmacokinetic interaction between simvastatin and fenofibrate with staggered and simultaneous dosing: Does it matter?

Anneke Winsemius, Jean-Claude Ansquer, Matthias Olbrich, Peter van Amsterdam et autres

Simvastatin and fenofibrate are frequently co-prescribed at staggered intervals for the treatment of dyslipidemia. Since a drug-drug interaction has been reported when the two drugs are given simultaneously, it is of clinical interest to know whether the interaction differs between simultaneous and …

ch (code pays fourni par la source)

Long-Term Effects of Fenofibric Acid + Statin Combination Therapy in Patients with High Triglycerides and Low HDL-C †

Kamlesh M. Thakker, Inderjit Mandair, Carolyn M. Setze, Jean-Claude Ansquer et autres

us (code pays fourni par la source)

P222 - Effet du fénofibrate sur la diméthylarginine symétrique et la diméthylarginine asymétrique chez des patients dyslipidémiques et diabétiques de type 2

Jean-Claude Ansquer, Paul Elie Valensi, R. Neil Dalton, Ingeborg Gottlieb et autres

de, fr, gb (code pays fourni par la source)

Fibrates and Statins in the Treatment of Diabetic Retinopathy

Jean-Claude Ansquer, Dominique Crimet, Christelle Foucher

Diabetic retinopathy (DR) is one of the leading risk factors and causes of blindness worldwide. Tight glucose and blood pressure control has been shown to significantly decrease the risk of development as well as the progression of retinopathy and represents the cornerstone …

be, fr (code pays fourni par la source)

Fenofibrate, Homocysteine and Renal Function

Christelle Foucher, Laurence Brugere, Jean-Claude Ansquer

Fibrates or PPAR alpha agonists, in particular fenofibrate, are known to increase homocysteine levels (Hcy). A 3 to 5 micromol/L increase in Hcy is commonly observed within the first few weeks of fenofibrate treatment; it then persists in plateau when treatment is …

fr (code pays fourni par la source)

Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

P. L. Drury, R. Ting, Diana Zannino, Christian Ehnholm et autres

au, fi, fr, nz (code pays fourni par la source)

Proof of concept study: does fenofibrate have a role in sleep apnoea syndrome?

Éric Bruckert, Emilie Duchêne, Dominique Bonnefont‐Rousselot, Boris Hansel et autres

OBJECTIVE: To investigate the effect of fenofibrate on sleep apnoea indices. METHODS: Proof-of-concept study comprising a placebo run-in period (1 week, 5 weeks if fibrate washout was required) and a 4-week randomized, double-blind treatment period. Thirty-four subjects (mean age 55 years, body …

fr (code pays fourni par la source)